Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;77(2):199-202.
doi: 10.1136/thoraxjnl-2021-217325. Epub 2021 Aug 6.

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

Simon Couillard  1   2 , Annette Laugerud  3 , Maisha Jabeen  4 , Sanjay Ramakrishnan  4   5 , James Melhorn  4 , Timothy Hinks  4 , Ian Pavord  4
Affiliations

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

Simon Couillard et al. Thorax. 2022 Feb.

Abstract

Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide (FeNO). Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1-2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for different patient groups. The resultant prototype risk scale shows potential to predict asthma attacks, which may be prevented by anti-inflammatory treatment.

Keywords: allergic lung disease; asthma; asthma epidemiology; clinical epidemiology; eosinophil biology; exhaled airway markers; pulmonary eosinophilia; respiratory measurement.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SC: has received a non-restricted research grant from Sanofi Genzyme for investigator-initiated type 2 innovation research and speaker honoraria from Sanofi/Regeneron, AstraZeneca and GlaxoSmithKline (GSK), all outside the submitted work. AL is an employee of Sanofi Norway. MJ has received grants from the University of Oxford and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). SR reports non-financial support from AstraZeneca and other sources of revenue from Australian Government Research Training Program and the NIHR Oxford BRC. JM has received grants from the NIHR Oxford BRC. TH has received grants from Pfizer, the University of Oxford, the Wellcome Trust, the Guardians of the Beit Fellowship and the NIHR Oxford BRC outside the submitted work. He has received personal fees from AstraZeneca, Teva and PeerVoice outside the submitted work. In the last 5 years, IP has received speaker’s honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine AB, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AstraZeneca, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, AstraZeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is a copatent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014–2015, he was an expert witness for a patent dispute involving AstraZeneca and Teva.

Figures

Figure 1
Figure 1
Prototype asthma attack risk scale. Numbers in each cell are predicted annual asthma attack rates for patients over the age of 12 if treatment is not changed. An asthma attack is an episode of acute asthma requiring treatment with systemic steroids ≥3 days and/or hospitalisation. The blood eosinophil count is contemporaneous or the highest result in the last 12 months; fractional exhaled nitric oxide level is contemporaneous. *Risk factors are defined by the Global Initiative for Asthma (GINA) guidelines: poor symptom control (Asthma Control Questionnaire score ≥1.5), low lung function (forced expiratory volume in 1 second <80% predicted), adherence issues, reliever overuse (>200 dose of salbutamol cannister/month), intubation or intensive care unit admission for asthma previously, comorbidities (one of chronic rhinosinusitis, obesity and psychiatric disease) and environmental exposures (one of smoking, allergen and pollution).
See this image and copyright information in PMC

References

    1. Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention (2021 update), 2021. Available: https://ginasthma.org/
    1. Lazarus SC, Boushey HA, Fahy JV, et al. . Long-Acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583–93. 10.1001/jama.285.20.2583 - DOI - PubMed
    1. Shrimanker R, Keene O, Hynes G, et al. . Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. Am J Respir Crit Care Med 2019;200:1308–12. 10.1164/rccm.201903-0599LE - DOI - PubMed
    1. Pavord ID, Holliday M, Reddel HK, et al. . Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med 2020;8:671–80. 10.1016/S2213-2600(20)30053-9 - DOI - PubMed
    1. Lee LA, Bailes Z, Barnes N, et al. . Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021;9:69–84. 10.1016/S2213-2600(20)30389-1 - DOI - PubMed

Publication types